Enigma negatively regulates p53 through MDM2 and promotes tumor cell survival in mice

Journal of Clinical Investigation

Volumn 120, Issue 12, 2010, Pages 4493-4506

  Jung, Cho Rok ^a   Lim, Jung Hwa ^a   Choi, Yoonjung ^a   Kim, Dae Ghon ^b   Kang, Koo Jeong ^c   Noh, Seung Moo ^d   Im, Dong Soo ^a  

^a Korea Research Institute of Bioscience and Biotechnology (KRIBB)   (South Korea)

^b Chonbuk National University Medical School   (South Korea)

^c Keimyung University School of Medicine   (South Korea)

^d Chungnam National University College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

FIBROBLAST GROWTH FACTOR; PDZ PROTEIN; PROTEIN ENIGMA; PROTEIN MDM2; PROTEIN P21; PROTEIN P53; SCATTER FACTOR; SERUM RESPONSE FACTOR; UBIQUITIN PROTEIN LIGASE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL SURVIVAL; COLON CARCINOMA; ENZYME ACTIVITY; HEPATOMA CELL; HUMAN; HUMAN TISSUE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN DOMAIN; PROTEIN PROTEIN INTERACTION; TUMOR CELL; UBIQUITINATION;

ANIMALS; APOPTOSIS; BASE SEQUENCE; CELL LINE, TUMOR; CELL SURVIVAL; CELLS, CULTURED; COLORECTAL NEOPLASMS; CYCLIN-DEPENDENT KINASE INHIBITOR P21; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MICE; MICE, KNOCKOUT; NEOPLASMS; PROTO-ONCOGENE PROTEINS C-MDM2; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; STOMACH NEOPLASMS; TUMOR SUPPRESSOR PROTEIN P53; UBIQUITINATION;

EID: 78649826395     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI42674     Document Type: Article

References (73)

1. Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature. 2000;408(6810):307-310.
2. Haupt Y, Maya R, Kazaz A, Oren M. Mdm2 promotes the rapid degradation of p53. Nature. 1997; 387(6630):296-299. (Pubitemid 27220766)
3. Honda R, Tanaka H, Yasuda H. Oncoprotein MDM2 is a ubiquitin ligase for tumor suppressor p53. FEBS Lett. 1997;420(1):25-27.
4. Kubbutat KHG, Jones SN, Vousden KH. Regulation of p53 stability by Mdm2. Nature. 1997; 387(6630):299-302.
5. Fang S, Jensen JP, Ludwig RL, Vousden KH, Weissman AM. Mdm2 is a RING finger-dependent ubiquitin protein ligase for itself and p53. J Biol Chem. 2000; 275(12):8945-8951.
6. Honda R, Yasuda H. Activity of MDM2, a ubiquitin ligase, toward p53 or itself is dependent on the RING finger domain of the ligase. Oncogene. 2000; 19(11):1473-1476.
7. Barak Y, Juven T, Haffner R, Oren M. mdm2 expression is induced by wild type-p53 activity. EMBO J. 1993;12(2):461-468.
8. Wu X, Bayle JH, Olson D, Levine AJ. The p53 mdm-2 autoregulatory feedback loop. Genes Dev. 1993;7(7A):1126-1132.
9. Itahana K, et al. Targeted inactivation of Mdm2 RING finger E3 ubiquitin ligase activity in the mouse reveals mechanistic insights into p53 regulation. Cancer Cell. 2007;12(4):355-366.
10. Linares LK, et al. Intrinsic ubiquitination activity of PCAF controls the stability of the oncoprotein Hdm2. Nat Cell Biol. 2007;9(3):331-338.
11. Michael D, Oren M. The p53-Mdm2 module and the ubiquitin system. Semin Cancer Biol. 2003; 13(1):49-58.
12. Horn HF, Vousden KH. Coping with stress: multiple ways to activate p53. Oncogene. 2007; 26(9):1306-1316.
13. Kruse J-P, Gu W. Modes of p53 regulation. Cell. 2009;137(4):609-622.
14. Toledo F, Wahl GM. Regulating the p53 pathway: in vitro hypotheses, in vivo veritas. Nat Rev Cancer. 2006;6(12):909-923. (Pubitemid 44862676)
15. Onel K, Cordon-Cardo C. MDM2 and prognosis. Mol Cancer Res. 2004;2(1):1-8.
16. Bach I. The LIM domain: regulation by association. Mech Dev. 2000;91(1-2):5-17.
17. Guy PM, Kenny DA, Gill GN. The PDZ domain of the LIM protein enigma binds to beta-tropomyosin. Mol Biol Cell. 1999;10(6):1973-1984.
18. Barrès R, et al. Enigma interacts with adaptor protein with PH and SH2 domains to control insulininduced actin cytoskeleton remodeling and glucose transporter 4 translocation. Mol Endocrinol. 2006; 20(11):2864-2875.
19. Durick K, Gill GN, Taylor SS. Shc and Enigma are both required for mitogenic signaling by Ret/ptc2. Mol Cell Biol. 1998;18(4):2298-2308. (Pubitemid 28152677)
20. Kuroda S, et al. Protein-protein interaction of zinc finger LIM domains with protein kinase C. J Biol Chem. 1996;271(49):31029-31032.
21. Wu R, Durick K, Songyang Z, Cantley LC, Taylor SS, Gill GN. Specificity of LIM domain interaction with receptor tyrosine kinases. J Biol Chem. 1996; 271(27):15934-15941.
22. Sangadala S, Boden SD, Viggeswarapu M, Liu Y, Titus L. LIM mineralization protein-1 potentiates bone morphogenetic protein responsiveness via a novel interaction with Smurf 1 resulting in decreased ubiquitination of Smads. J Biol Chem. 2006; 281(25):17212-17219. (Pubitemid 43909529)
23. Krcmery J, Camarata T, Kulisz A, Simon HG. Nucleocytoplasmic functions of the PDZ-LIM protein family: new insights into organ development. BioEssays. 2010;32(2):100-108.
24. El-Deiry WS, et al. WAF1, a potential mediator of p53 tumor suppression. Cell. 1993;75(4):817-825.
25. Jung CR, et al. Adenovirus-mediated transfer of siRNA against PTTG1 inhibits liver cancer cell growth in vitro and in vivo. Hepatology. 2006; 43(5):1042-1052.
26. Miyashita T, et al. Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. Oncogene. 1994;9(6):1799-1805.
27. Moustakas A, Kardassism D. Regulation of the human p21/WAF1/Cip1 promoter in hepatic cells by functional interactions between Sp1 and Smad family members. Proc Natl Acad Sci. U. S. A. 1998; 95(15):8733-8738.
28. Chen J, Marechal V, Levine AJ. Mapping of the p53 and mdm-2 interaction domains. Mol Cell Biol. 1993; 13(7):4107-4014.
29. Levav-Cohen Y, Haupt S, Haupt Y. Mdm2 in growth signaling and cancer. Growth Factors. 2005; 23(3):183-192.
30. Chai J, Tarnawski AS. Serum response factor: discovery, biochemistry, biological roles and implications for tissue injury healing. J Physiol Pharmacol. 2002; 53(2):147-157.
31. Niu Z, Li A, Zhang SX, Schwartz RJ. Serum response factor micromanaging cardiogenesis. Curr Opin Cell Biol. 2007;19(6):618-627. (Pubitemid 350216421)
32. Berkovich E, Lamed Y, Ginsberg D. E2F and Ras synergize in transcriptionally activating p14ARF expression. Cell Cycle. 2003;2(2):127-133.
33. Lim JH, Jung CR, Lee CH, Im DS. Egr-1 and serum response factor are involved in growth factors- and serum-mediated induction of E2-EPF UCP expression that regulates the VHL-HIF pathway. J Cell Biochem. 2008;105(4):1117-1127.
34. Roos F, Ryan AM, Chamow SM, Bennett GL, Schwall RH. Induction of liver growth in normal mice by infusion of hepatocyte growth factor/scatter factor. Am J Physiol. 1995;268(2 pt 1):G380-G386.
35. Le MT, et al. MicroRNA-125b is a novel negative regulator of p53. Genes Dev. 2009;23(7):862-876.
36. Park MY, et al. Expression of the serum response factor in hepatocellular carcinoma: implications for epithelial-mesenchymal transition. Int J Oncol. 2007;31(6):1309-1315.
37. Jung CR, et al. E2 - EPF UCP targets pVHL for degradation and associates with tumor growth and metastasis. Nat Med. 2006;12(7):809-816.
38. Momand J, Jung D, Wilczynski S, Niland J. The MDM2 gene amplification database. Nucleic Acids Res. 1998;26(15):3453-3458.
39. Endo K, Ueda T, Ohta T, Terada T. Protein expression of MDM2 and its clinicopathological relationships in human hepatocellular carcinoma. Liver. 2000; 20(3):209-215.
40. Gorgoulis VG, et al. A molecular and immunohistochemical study of the MDM2 protein isoforms and p53 gene product in bronchogenic carcinoma. J Pathol. 1996;180(2):129-137.
41. Kasper HU, Schneider-Stock R, Mellin W, Günther T, Roessner A. P53-protein accumulation and MDM2-protein overexpression in gastric carcinomas. No apparent correlation with survival. Pathol Res Pract. 1999;195(12):815-820.
42. Lianes P, et al. Altered patterns of MDM2 and TP53 expression in human bladder cancer. J Natl Cancer Inst. 1994;86(17):1325-1330.
43. Cadwell C, Zambetti GP. The effects of wild - type p53 tumor suppressor activity and mutant p53 gain - of - function. Gene. 2001;277(1-2):15-30. (Pubitemid 32972107)
44. Sigal A, Rotter V. Oncogenic mutations of the p53 tumor suppressor: the demons of the quardian of the genome. Cancer Res. 2000;60(24):6788-6793. (Pubitemid 32059139)
45. Momand J, Zambetti GP, Olson DC, George D, Levine AJ. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell. 1992;69(7):1237-1245.
46. Marine JC, Francoz S, Maetens M, Wahl G, Lozano G. Keeping p53 in check: essential and synergistic functions of Mdm2 and Mdm4. Cell Death Differ. 2006; 13(6):927-934.
47. Stommel JM, Wahl GM. Accelerated MDM2 autodegradation induced by DNA-damaged kinases is required for p53 activation. EMBO J. 2004; 23(7):1547-1558.
48. Jones SN, Roe AE, Donehower LA, Bradley A. Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53. Nature. 1995;378(6553):206-208.
49. Montes de Oca Luna R, Wagner DS, Lozano G. Rescue of early embryonic lethality in mdm2- deficient mice by deletion of p53. Nature. 1995; 378(6553):203-206.
50. Poyurovsky MV, et al. The Mdm2 RING domain Cterminus is required for supramolecular assembly and ubiquitin ligase activity. EMBO J. 2007;26(1):90-101.
51. Uldrijan S, Pannekoek WJ, Vousden KH. An essential function of the extreme C-terminus of MDM2 can be provided by MDMX. EMBO J. 2007;26(1):102-112. (Pubitemid 46094703)
52. Cheng Q, Chen L, Li Z, Lane WS, Chen J. ATM activates p53 by regulating MDM2 oligomerization and E3 processivity. EMBO J. 2009;28(24):3857-3867.
53. Linares LK, Hengstermann A, Ciechanover A, Müller S, Scheffner M. HdmX stimulates Hdm2-mediated ubiquitination and degradation of p53. Proc Natl Acad Sci U S A. 2003;100(21):12009-12014.
54. Wallace M, Worrall E, Pettersson S, Hupp TR, Ball KL. Dual-site regulation of MDM2 E3-ubiquitin ligase activity. Mol Cell. 2006;23(2):251-263.
55. Ganguli G, Wasylyk B. p53-independent functions of MDM2. Mol Cancer Res. 2003;1(14):1027-1035.
56. Mayo LD, Donner DB. A phosphatidylinositol 3-kinase/Akt pathway promotes translocation of Mdm2 from the cytoplasm to the nucleus. Proc. Natl. Acad. Sci. U S A. 2001;98(20):11598-11603.
57. Zhou BP, Liao Y, Xia W, Zou Y, Spohn B, Hung MC. HER-2/neu induces p53 ubiquitination via Akt-mediated MDM2 phosphorylation. Nat Cell Biol. 2001;3(11):973-982. (Pubitemid 34428742)
58. Ashcroft M, et al. Phosphorylation of HDM2 by Akt. Oncogene. 2002;21(13):1955-1962.
59. Jackson MW, Patt LE, LaRusch GA, Donner DB, Stark GR, Mayo LD. Hdm2 nuclear export, regulated by insulin-like growth factor-I/MAPK/p90Rsk signaling, mediates the transformation of human cells. J Biol Chem. 2006;281(24):16814- 16820.
60. Feng J, et al. Stabilization of Mdm2 via decreased ubiquitination is mediated by protein kinase B/ Akt-dependent phosphorylation. J Biol Chem. 2004; 279(34):35510-35517. (Pubitemid 39100551)
61. Maya R, et al. ATM - dependent phosphorylation of Mdm2 on serine 395: role in p53 activation by DNA damage. Genes Dev. 2001;15(9):1067-1077.
62. Weber HO, Ludwig RL, Morrison D, Kotlyarov A, Gaestel M, Vousden KH. HDM2 phosphorylation by MAPKAP kinase 2. Oncogene. 2005;24(12):1965-1972.
63. Roth J, Dobbelstein M, Freedman DA, Shenk T, Levine AJ. Nucleo-cytoplasmic shuttling of the hdm2 oncoprotein regulates the levels of the p53 protein via a pathway used by the human immunodeficiency virus rev protein. EMBO J. 1998;17(2):554-564.
64. Li M, Brooks CL, Wu-Baer F, Chen D, Baer R, Gu W. Mono- versus polyubiquitination: differential control of p53 fate by Mdm2. Science. 2003; 302(5652):1972-1975. (Pubitemid 37523506)
65. Xirodimas DP, Stephen CW, Lane DP. Cocompartmentalization of p53 and Mdm2 is a major determinant for Mdm2-mediated degradation of p53. Exp Cell Res. 2001;270(1):66-77.
66. Shirangi TR, Zaika A, Moll UM. Nuclear degradation of p53 occurs during down-regulation of the p53 response after DNA damage. FASEB J. 2002; 16(3):420-422.
67. Wang YV, Wade M, Wong E, Rodewald LW, Wahl GM. Quantitative analyses reveal the importance of regulated Hdmx degradation for p53 activation. Proc Natl Acad Sci U S A. 2007;104(30):12365-12370.
68. Mendrysa SM, et al. Tumor suppression and normal aging in mice with constitutively high p53 activity. Genes Dev. 2006;20(1):16-21.
69. Bond GL, et al. A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell. 2004;119(5):591-602.
70. Klein A, et al. Identification of brain- and bone-specific breast cancer metastasis genes. Cancer Lett. 2009; 276(2):212-220.
71. Yanglin P, et al. KCNE2, a down - regulated gene identified by in silico analysis, suppressed proliferation of gastric cancer cells. Cancer Lett. 2007; 246(1-2):129-138.
72. Choi JY, et al. Adenovirus-mediated p53 tumor suppressor gene therapy against subcutaneous HuH7 hepatoma cell line nodule of nude mice. J Korean Med Sci. 1999;14(3):271-276.
73. Barboza JA, Iwakuma T, Terzian T, El-Naggar K, Lozano G. Mdm2 and Mdm4 loss regulates distinct p53 activities. Mol Cancer Res. 2008;6(6):947-954.